Nav: Home

New HPV vaccine could curb cervical cancers and health costs if adopted widely

April 18, 2016

New Haven, Conn.-- A Yale-led study finds that a new vaccine for human papillomavirus (HPV) would significantly reduce both cervical cancer incidence and healthcare costs if states coordinated policies to improve coverage.

The study was published April 18 by Proceedings of the National Academy of Sciences.

HPV, the most common sexually transmitted infection in the United States, is the primary cause of cervical cancer. A new vaccine available since 2015, Gardasil 9, provides protection against nine different HPV types, including five cancer-causing types that were not included in older vaccines. A team of researchers at Yale School of Public Health and the University of Waterloo developed a transmission model to determine the potential impact of the vaccine on cervical cancer incidence and healthcare costs.

The novel model took into account several factors affecting HPV transmission and cervical cancer progression. It incorporated 10 HPV types, demographics, age, sexual behavior, as well as state-specific vaccine policy and migration patterns.

The researchers found that switching to Gardasil 9 would result in greater health benefits at the same or lower cost. Specifically, the new vaccine would decrease cervical cancer incidence by 73%, compared to 63% with the older vaccines, and reduce mortality by 49% versus 43%.

The study also determined that these improvements could be realized at the same or lower cost despite the higher per-dose cost of Gardasil 9. Notably, their finding of increased cost-effectiveness holds whether vaccination rates increase or stay the same, said first author David Durham, associate research scientist at the Center for Infectious Disease Modeling and Analysis (CIDMA) at Yale School of Public Health. "Adopting the new vaccine is always cost-effective relative to the old vaccines," he noted.

In addition, efforts to expand HPV vaccination, particularly in states with low coverage, could prevent even more cancers and deaths, said the researchers, adding that due to interstate migration, all states would benefit if they aligned vaccination policy. "The greatest benefits of HPV vaccination both in terms of cancer reduction and health care costs are realized when policy promoting vaccination is coordinated across states," said Alison Galvani, the Burnett and Stender Families Professor of Epidemiology and director of CIDMA.

Furthermore, increased funding to states could improve vaccine coverage and public health, the researchers noted. Durham pointed to funds provided by states and the Centers for Disease Control and Prevention's (CDC) Prevention and Public Health Fund. More resources "do lead to improvements in coverage," he said. "In terms of number of cancers averted per vaccine, there are decreasing marginal returns in states that already have high coverage. You get more bang for your buck by focusing first on states with lower coverage."

The CDC currently recommends vaccination for females aged 11-26 and males aged 11-21. Three doses are recommended for lasting protection against cervical cancer, the researchers said. HPV is common in both males and females, and can cause cancers of the anus, mouth/throat and penis in males.
-end-
Additional study authors include Martial Loth Ndeffo Mbah, Laura A. Skrip, Forrest K. Jones, and Chris T. Bauch.

This research was funded by the National Institutes of Health, the James S. McDonnell Foundation, and the Canadian Institutes of Health Research.

Citation: Proceedings of the National Academy of Sciences

Yale University

Related Cancer Articles:

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Teaching For Better Humans 2.0
More than test scores or good grades–what do kids need for the future? This hour, TED speakers explore how to help children grow into better humans, both during and after this time of crisis. Guests include educators Richard Culatta and Liz Kleinrock, psychologist Thomas Curran, and writer Jacqueline Woodson.
Now Playing: Science for the People

#556 The Power of Friendship
It's 2020 and times are tough. Maybe some of us are learning about social distancing the hard way. Maybe we just are all a little anxious. No matter what, we could probably use a friend. But what is a friend, exactly? And why do we need them so much? This week host Bethany Brookshire speaks with Lydia Denworth, author of the new book "Friendship: The Evolution, Biology, and Extraordinary Power of Life's Fundamental Bond". This episode is hosted by Bethany Brookshire, science writer from Science News.
Now Playing: Radiolab

Dispatch 3: Shared Immunity
More than a million people have caught Covid-19, and tens of thousands have died. But thousands more have survived and recovered. A week or so ago (aka, what feels like ten years in corona time) producer Molly Webster learned that many of those survivors possess a kind of superpower: antibodies trained to fight the virus. Not only that, they might be able to pass this power on to the people who are sick with corona, and still in the fight. Today we have the story of an experimental treatment that's popping up all over the country: convalescent plasma transfusion, a century-old procedure that some say may become one of our best weapons against this devastating, new disease.   If you have recovered from Covid-19 and want to donate plasma, national and local donation registries are gearing up to collect blood.  To sign up with the American Red Cross, a national organization that works in local communities, head here.  To find out more about the The National COVID-19 Convalescent Plasma Project, which we spoke about in our episode, including information on clinical trials or plasma donation projects in your community, go here.  And if you are in the greater New York City area, and want to donate convalescent plasma, head over to the New York Blood Center to sign up. Or, register with specific NYC hospitals here.   If you are sick with Covid-19, and are interested in participating in a clinical trial, or are looking for a plasma donor match, check in with your local hospital, university, or blood center for more; you can also find more information on trials at The National COVID-19 Convalescent Plasma Project. And lastly, Tatiana Prowell's tweet that tipped us off is here. This episode was reported by Molly Webster and produced by Pat Walters. Special thanks to Drs. Evan Bloch and Tim Byun, as well as the Albert Einstein College of Medicine.  Support Radiolab today at Radiolab.org/donate.